Well, centralization is a key point overall in all the fields of surgical oncology. This is all the more true for rare tumors like retroperitoneal sarcoma. So we have data that the outcome of these patients is improving with an increasing volume of the referral centers. Just consider that in the series from the US, from the United States, the majority of patients, more than 90% of patients affected by retroperitoneal sarcoma are treated in centers with a volume of less than 10 patients per year...
Well, centralization is a key point overall in all the fields of surgical oncology. This is all the more true for rare tumors like retroperitoneal sarcoma. So we have data that the outcome of these patients is improving with an increasing volume of the referral centers. Just consider that in the series from the US, from the United States, the majority of patients, more than 90% of patients affected by retroperitoneal sarcoma are treated in centers with a volume of less than 10 patients per year. And so this is very rare. In general speaking, we consider a high-volume center, a center that is treating more than 13 to 16 patients per year. So this is critical, especially when you consider the national situation, the local situation in a country, the countries may be very large where you cannot have only a few centers, you need to cover also the geography of the country, so it’s very complex, it has to deal also with oncology policy and the local organization, but in general speaking, it’s always true that the more you increase the volume, the more you are able to improve the outcomes.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
